TheraCryf plc Reports Strong Progress and Strategic Focus in 2025 Results

An update from Evgen Pharma ( (GB:TCF) ) is now available.

TheraCryf plc announced its full-year results for the period ending March 31, 2025, highlighting significant progress in its drug development programs, particularly the orexin-1 antagonist for addiction treatment. The company raised £5.15 million, extending its cash runway to the end of 2026, and completed the acquisition of Chronos Therapeutics. TheraCryf is now in the top 20% of European listed biotech companies by cash runway duration. The strategic focus on brain disorders, especially the Ox-1 program, positions the company for substantial growth, with plans to achieve clinical readiness by late 2026. The appointment of Dr. Alastair Smith as Chair and the resolution of a dispute with partner Stalicla SA are expected to further strengthen TheraCryf’s market position.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical-stage drug development company focused on brain disorders, with a broad pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets to achieve preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is listed on AIM in London under the ticker symbol TCF.

Average Trading Volume: 4,582,387

Technical Sentiment Signal: Sell

Current Market Cap: £5.91M

See more data about TCF stock on TipRanks’ Stock Analysis page.